Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Feliza Mirasol is the science editor for 

Articles

With these agreements, the respective parties will work to advance therapeutic candidates for treating fibrotic diseases, osteoarthritis, and Alzheimer’s disease.

GSK Enters into Strategic Collaborations with Relation and Muna to Advance Drug Development

Novartis will in-license PTC's PTC518 program, which has the potential become the first oral disease-modifying therapy for Huntington's disease.

Novartis Enters $2.9 Billion License Agreement with PTC Therapeutics for Huntington’s Disease Development Program

Cheryl Barton is director of PharmaVision, 

Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to innovative cell and gene therapies.

European Biotechs Unlocking Parkinson’s Disease

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Automation technologies provide real potential to improve responsiveness and decision-making in drug development.

Integrating Advanced Technologies for Pharma Analysis

LNPs have gained solid ground as a drug delivery system for mRNA due to their success in the vaccines arena.

Exploring Opportunities for LNP Delivery in mRNA

Through the agreement, Cambrex will provide accelerated access to clinical development capabilities to Lilly’s biotech collaborators.

Cambrex Enters Agreement with Lilly to Support Biotech Collaborator Manufacturing 

EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.

Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert

With its new offering, Lonza can tailor services to support smart capsule companies with its bi-layer capsule manufacturing technology.

Lonza to Provide Tailored Offering for the Development of Oral Biologics Using Smart Capsules

Datwyler has launched new coated plungers in its NeoFlex line that are suitable for large volume biologics.

Coated Plungers for Large Volume Biologics

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.